Loading clinical trials...
Loading clinical trials...
A Phase I, Multi-centre, Double-blind, Placebo-controlled Parallel Group Study to Assess the pharmacoMRI Effects of AZD6765 in Male and Female Subjects Fulfilling the Criteria for Major Depressive Disorder
Conditions
Interventions
AZD6765
Ketamine
+1 more
Locations
2
United Kingdom
Research Site
Manchester, United Kingdom
Research Site
Oxford, United Kingdom
Start Date
December 1, 2009
Primary Completion Date
March 1, 2011
Completion Date
March 1, 2011
Last Updated
October 13, 2014
NCT07360600
NCT06793397
NCT07478393
NCT04123314
NCT06906939
NCT05851898
Lead Sponsor
AstraZeneca
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions